Macquarie Group
TSHA icon

Macquarie Group’s Taysha Gene Therapies TSHA Stock Holding History

Macquarie Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,066
Closed -$23 – 2142
2024
Q1 		$23 Buy
+8,066
New +$16.8K ﹤0.01% 1686
2022
Q2 		– Sell
-867
Closed -$6 – 2627
2022
Q1 		$6 Hold
867
– – ﹤0.01% 2582
2021
Q4 		$10K Sell
867
-1,343
-61% -$20.3K ﹤0.01% 2517
2021
Q3 		$41K Buy
+2,210
New +$42K ﹤0.01% 2283

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Macquarie Group's TSHA Position: Q2 2024 in Review

Macquarie Group sold out of Taysha Gene Therapies (TSHA) in Q2 2024, closing a stake of 8,066 shares — an estimated $23 sold.

Macquarie Group first reported a position in TSHA in Q3 2021 and held it in 4 quarters. The position peaked at $41K in Q3 2021. 107 funds tracked by Wall St. Rank hold TSHA as of Q2 2024.

  • Macquarie Group reported no remaining Taysha Gene Therapies position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 8,066 Taysha Gene Therapies shares in Q2 2024, an estimated $23.
  • Macquarie Group first reported a position in Taysha Gene Therapies in Q3 2021 and held it in 4 quarters.
  • Macquarie Group's Taysha Gene Therapies position peaked at $41K in Q3 2021.
  • 107 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.